
Kidney Health Australia

EVIDENCE REPORT

SUMMARY 2021



MAKE THE LINK

Kidneys, Diabetes & Heart



KEY MESSAGES

GEW |

CKD rarely occurs in isolation and frequently occurs alongside diabetes and cardiovascular disease.

29%

of Australian adults are affected by **one or more** of CKD, Diabetes and CVD.



The most disadvantaged Australians experience a disproportionate burden of CKD, diabetes and cardiovascular disease and a higher rate of comorbidity of these conditions.



Over one-third of Aboriginal and Torres Strait Islander peoples have one or more of CKD, diabetes or cardiovascular disease. These conditions occur at a younger age and progress faster than in non-indigenous individuals.

1in **3**

hospitalisations involve diabetes, cardiovascular disease and/or CKD (including dialysis)




Psychosocial factors – depression, quality of life, cognitive impairment – have complex and multidirectional associations with CKD, diabetes and cardiovascular disease.



Depression is highly prevalent in persons with CKD, diabetes and cardiovascular disease.

WHAT THIS EVIDENCE REVIEW ADDS TO THE EXISTING LITERATURE IS:





A more holistic view of the health burden associated with comorbid CKD, diabetes, and cardiovascular disease in Australia.



Details on the current evidence concerning the impact of CKD, diabetes, cardiovascular disease and their comorbidity on mental health (Chapter 5). Given the increasing health burden related to dementia in Australia [67], the implications of comorbid CKD, diabetes and cardiovascular disease for cognitive aging are of critical importance.

Chronic kidney disease, diabetes and cardiovascular disease together affect 29% of Australian adults and frequently occur together.




Based on most recent estimates [1, 2]:



of the Australian adult population is affected by CKD. **2.4** million

Australian adults estimated to be affected by CKD (2018), an estimated 50% were over 65 years and 30% over 75 years.



< 1 in 10 Australians with CKD are aware of their condition.



Prevalence of self-reported **diabetes** (2017-18), true prevalence is likely higher.



Prevalence of self-reported heart, stroke and vascular disease among Australian adults (2017-18), with another 13% self-reporting a diagnosis of hypertension.



The prevalence of all three conditions increases steadily with increasing age.

CKD, diabetes and cardiovascular disease are inextricably linked, with interrelated biological pathways and shared risk factors.



Physical inactivity



Poor nutrition



Overweight & obesity



High blood pressure



Smoking



Harmful use of alcohol






High blood cholesterol



resistance

5.6 million


Australians have at least 1 of these three conditions



Rates of kidney failure due to diabetes have been

increasing

by 2.2% per year



Diabetes and hypertension cause over **half of all kidney failure** cases in Australia

THE BURDEN OF COMORBID DISEASE IS **UNEQUALLY DISTRIBUTED** ACROSS THE AUSTRALIAN POPULATION



CKD, diabetes and cardiovascular disease are most prevalent among the **most** disadvantaged Australians.



Australian adults in the lowest socioeconomic group are more than twice as likely to have 2 or more comorbid diagnoses of CKD, diabetes or cardiovascular disease compared to adults in the highest socioeconomic group [1].



Rates of death in association with CKD, diabetes and/or cardiovascular disease increase with greater geographical remoteness and greater socio-economic disadvantage.



People living in outer regional and remote areas were twice as likely to have all three of CKD, diabetes and cardiovascular disease compared to people living in major cities [1].

ABORIGINAL AND TORRES STRAIT ISLANDER PEOPLES EXPERIENCE A **HIGHER BURDEN** OF **COMORBID CKD**, **DIABETES** AND **CARDIOVASCULAR DISEASE**.






Over **one-third** of Aboriginal and Torres Strait Islander peoples have **one or more** of CKD, diabetes or cardiovascular disease.

- Appear at a younger age
 - Progress faster
- Co-occur more frequently
 Are associated with more complications

of all Aboriginal and Torres Strait Islander deaths listed **all three conditions** on the death certificate, compared to less than 2% of non-Indigenous deaths.

SOCIAL DETERMINANTS OF HEALTH AND PATHWAYS TO CKD, DIABETES AND CARDIOVASCULAR DISEASE IN ABORIGINAL AND TORRES STRAIT ISLANDER PEOPLES. INTERGENERATIONAL TRAUMA **ENVIRONMENTAL FACTORS** Social determinants · Adverse Interuterine environment · Overcrowded housing · Lack of control/agency · Economic disadvantage · Environmental stressors/lack of · Limited access to primary health personal security · Lower educational attainment · Exposure to stressful life events · Marginalisation · Poor nutrition High rates of lifestyle High rates of psychological High rates of infectious Untreated risk factors distress and depression related risk factors diseases Biomedical risk factors · Inflammatory responses Impaired fasting · Vascular injury High blood Obesity glucose/insulin pressure · Endothelial dysfunction resistance DEMENTIA CVD · CANCER CKD · INFECTION DM DEATH

THE RIPPLE EFFECT: MULTIMORBIDITY HAS IMPORTANT IMPLICATIONS FOR HEALTHY BRAIN AGING



Relationship between chronic kidney disease (CKD), diabetes, cardiovascular disease (CVD) and mental health, and knock-on effects on social functioning, financial security, care dependency and hospitalisations.

COMORBID CKD **INCREASES THE COSTS** ASSOCIATED WITH DIABETES AND CARDIOVASCULAR DISEASE.

The presence of comorbid CKD in diabetes and cardiovascular disease increases costs to the health system through:



Increased rates of hospitalisation



Increased **length** of hospitalisation



Increased **complexity** of medical management



The presence of Stage 3-5 CKD (excluding dialysis and transplant recipients) **increased** direct per person **health care costs** in people with diabetes by **57%** on average, compared to the cost of diabetes alone [47].



Increased rates of **adverse events and complications**, and increased risk of onset of kidney failure requiring kidney replacement therapy (KRT).



The **annual cost** to provide dialysis and transplantation to the 25,652 patients receiving KRT **exceeds \$1 billion** [45,48].

THE ONSET OF COMORBID CKD IS ASSOCIATED WITH SIGNIFICANTLY WORSE PROGNOSIS AND QUALITY OF LIFE

Patient-centred treatment approaches are needed that consider both physical and mental health



Individuals with comorbid CKD, diabetes and/or cardiovascular disease experience greater disease

severity, significantly worse quality of life, and **poorer prognosis** than individuals with any one condition in isolation.

The presence of any one of CKD, diabetes or cardiovascular disease increases the likelihood of having depression and is associated with reduced quality of life.

The onset of CKD causes **worsening** of depressive symptoms and further **reductions** in quality of life.

Caring for someone with kidney failure has a major impact on relationships and disrupts roles within the family [41].



It is critical that health systems consider the

interrelationships

between CKD, diabetes and cardiovascular disease and respond with integrated

prevention strategies, clinical care pathways and broader support systems.

The **impact** of an individual's disease on **family and friends**, feeling unwell, low mood, insufficient home care and other life stressors are ot

mood, insufficient home care and other life stressors are other key factors that increase the likelihood of **low self-reported quality of life** in CKD ^[28].



CKD exacerbates the **psychosocial burden** of diabetes and cardiovascular disease while compounding the **physical symptom burden** ^[26, 27].

A **LONG-TERM**, **COORDINATED** APPROACH TO THE PREVENTION OF CKD, DIABETES AND CARDIOVASCULAR DISEASE IS NEEDED.



Reduce the risk

Reducing the prevalence of risk factors for the onset of kidney damage, insulin resistance, hypertension, atherosclerosis and dyslipidaemia.



Improving access

Improving access to primary health care and preventive therapies for Aboriginal and Torres Strait Islander peoples and Australians who are socioeconomically disadvantaged or reside in remote areas.



Early detection

Early detection of CKD, diabetes and cardiovascular disease through targeted population screening.



Careful management

Careful management of disease from its earliest stages to prevent complications and adverse events, including access to new therapies.



Support

Provision of adequate psychosocial support to enable people to manage their own disease as effectively as possible, to prevent adverse mental health outcomes, and to support healthy cognitive aging.

About Kidney Health Australia

Kidney Health Australia has a clear purpose. We want to achieve good kidney health for all Australians. As the peak body for kidney health in Australia, we bring together the many voices within the kidney community, advocating on their behalf for health initiatives that will improve their quality of life. We strive to create a healthier community through increased awareness and detection of kidney disease and connect kidney patients to resources and services to help them manage their condition and improve their quality of life. For over 50 years, we have worked with the clinical and research community to support treatment and research improvements and innovations to foster a future without kidney disease.

Acknowledgments

This report has been commissioned and published by Kidney Health Australia under the guidance of Associate Professor Shilpa Jesudason, and Breonny Robson. The report was written by Sarah White. Clinical review of this report was undertaken by the Primary care Education Advisory committee for Kidney Health Australia (PEAK).

Citation: White SL. Chronic Kidney Disease, Diabetes & Cardiovascular Disease: Evidence Report 2021. Kidney Health Australia, Melbourne, Australia, March 2021. The full report is available from www.kidney.org. au This report was funded through an unrestricted sponsorship from Boehringer Ingelheim and Eli Lilly. In no way has Boehringer Ingelheim or Lilly had any part in the direction, analysis or findings contained within this report.

Contact Us

kidney.org.au Freecall 1800 454 363 careteam@kidney.org.au

